Combigan

Combigan is a brand name of brimonidine/timolol ophthalmic, approved by the FDA in the following formulation(s):

COMBIGAN (brimonidine tartrate; timolol maleate - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: October 30, 2007
  
  Strength(s): 0.2%;0.5% ^[RLD]

Has a generic version of Combigan been approved?

No. There is currently no therapeutically equivalent version of Combigan available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Combigan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Combination of brimonidine timolol for topical ophthalmic use
  Patent 7,030,149
  Issued: April 18, 2006
  Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
  Assignee(s): Allergan, Inc.
  Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
  
  Patent expiration dates:
  
  
  • April 19, 2022
    
    ✓ 
    Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
  
  



• 
  Combination of brimonidine and timolol for topical ophthalmic use
  Patent 7,320,976
  Issued: January 22, 2008
  Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
  Assignee(s): Allergan, Inc.
  Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
  
  Patent expiration dates:
  
  
  • April 19, 2022
    
    ✓ 
    Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
  
  



• 
  Combination of brimonidine and timolol for topical ophthalmic use
  Patent 7,323,463
  Issued: January 29, 2008
  Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
  Assignee(s): Allergan, Inc.
  Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
  
  Patent expiration dates:
  
  
  • January 19, 2023
    
    ✓ 
    Drug product
  
  



• 
  Combination of brimonidine and timolol for topical ophthalmic use
  Patent 7,642,258
  Issued: January 5, 2010
  Inventor(s): Chang; Chin-Ming & Beck; Gary J. & Pratt; Cynthia C. & Batoosingh; Amy L.
  Assignee(s): Allergan, Inc.
  Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
  
  Patent expiration dates:
  
  
  • April 19, 2022
    
    ✓ 
    Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 30, 2010 - NEW COMBINATION
  
  

See also...

• Combigan Consumer Information (Drugs.com)
• Combigan Drops Consumer Information (Wolters Kluwer)
• Combigan Consumer Information (Cerner Multum)
• Combigan Advanced Consumer Information (Micromedex)
• Brimonidine/Timolol Drops Consumer Information (Wolters Kluwer)
• Brimonidine and timolol ophthalmic Consumer Information (Cerner Multum)
• Brimonidine and timolol Ophthalmic Advanced Consumer Information (Micromedex)